Cargando…
Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
Malignant tumors remain the health problem of highest concern among people worldwide due to its high mortality and recurrence. Lung, gastric, liver, colon, and breast cancers are among the top five malignant tumors in terms of morbidity and mortality. In cancer biology, aberrant signaling pathway re...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203325/ https://www.ncbi.nlm.nih.gov/pubmed/34135756 http://dx.doi.org/10.3389/fphar.2021.675675 |
_version_ | 1783708148149780480 |
---|---|
author | He, Hongdan Shao, Xiaoni Li, Yanan Gihu, Ribu Xie, Haochen Zhou, Junfu Yan, Hengxiu |
author_facet | He, Hongdan Shao, Xiaoni Li, Yanan Gihu, Ribu Xie, Haochen Zhou, Junfu Yan, Hengxiu |
author_sort | He, Hongdan |
collection | PubMed |
description | Malignant tumors remain the health problem of highest concern among people worldwide due to its high mortality and recurrence. Lung, gastric, liver, colon, and breast cancers are among the top five malignant tumors in terms of morbidity and mortality. In cancer biology, aberrant signaling pathway regulation is a prevalent theme that drives the generation, metastasis, invasion, and other processes of all malignant tumors. The Wnt/β-catenin, PI3K/AKT/mTOR, Notch and NF-kB pathways are widely concerned and signal crosstalks exist in the five solid tumors. This review provides an innovative summary of the recent progress in research on these signaling pathways, the underlying mechanism of the molecules involved in these pathways, and the important role of some miRNAs in tumor-related signaling pathways. It also presents a brief review of the antitumor molecular drugs that target these signaling pathways. This review may provide a theoretical basis for the study of the molecular biological mechanism of malignant tumors and vital information for the development of new treatment strategies with a focus on efficacy and the reduction of side effects. |
format | Online Article Text |
id | pubmed-8203325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82033252021-06-15 Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges He, Hongdan Shao, Xiaoni Li, Yanan Gihu, Ribu Xie, Haochen Zhou, Junfu Yan, Hengxiu Front Pharmacol Pharmacology Malignant tumors remain the health problem of highest concern among people worldwide due to its high mortality and recurrence. Lung, gastric, liver, colon, and breast cancers are among the top five malignant tumors in terms of morbidity and mortality. In cancer biology, aberrant signaling pathway regulation is a prevalent theme that drives the generation, metastasis, invasion, and other processes of all malignant tumors. The Wnt/β-catenin, PI3K/AKT/mTOR, Notch and NF-kB pathways are widely concerned and signal crosstalks exist in the five solid tumors. This review provides an innovative summary of the recent progress in research on these signaling pathways, the underlying mechanism of the molecules involved in these pathways, and the important role of some miRNAs in tumor-related signaling pathways. It also presents a brief review of the antitumor molecular drugs that target these signaling pathways. This review may provide a theoretical basis for the study of the molecular biological mechanism of malignant tumors and vital information for the development of new treatment strategies with a focus on efficacy and the reduction of side effects. Frontiers Media S.A. 2021-05-31 /pmc/articles/PMC8203325/ /pubmed/34135756 http://dx.doi.org/10.3389/fphar.2021.675675 Text en Copyright © 2021 He, Shao, Li, Gihu, Xie, Zhou and Yan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology He, Hongdan Shao, Xiaoni Li, Yanan Gihu, Ribu Xie, Haochen Zhou, Junfu Yan, Hengxiu Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges |
title | Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges |
title_full | Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges |
title_fullStr | Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges |
title_full_unstemmed | Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges |
title_short | Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges |
title_sort | targeting signaling pathway networks in several malignant tumors: progresses and challenges |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203325/ https://www.ncbi.nlm.nih.gov/pubmed/34135756 http://dx.doi.org/10.3389/fphar.2021.675675 |
work_keys_str_mv | AT hehongdan targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges AT shaoxiaoni targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges AT liyanan targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges AT gihuribu targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges AT xiehaochen targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges AT zhoujunfu targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges AT yanhengxiu targetingsignalingpathwaynetworksinseveralmalignanttumorsprogressesandchallenges |